Skip to menu Skip to content Skip to footer
Professor Simon Cool
Professor

Simon Cool

Email: 
Phone: 
+61 7 336 54175

Overview

Background

Professor Simon Cool is Professor of Bioengineering and Director of the UQ Advanced Cell Therapy Manufacturing Initiative in the School of Chemical Engineering at the University of Queensland.

Professor Cool began his scientific career at the University of Queensland more than 20 years ago. He received his BSc (hons) and PhD degrees from the University of Queensland, where he subsequently held a faculty position in the School of Biomedical Sciences. His areas of studies have included age-related changes in the structure of bone and teeth and the extracellular matrix compartment of skeletal tissue that guide stem cell behaviour and wound repair. Professor Cool was invited to join the Institute of Molecular and Cell Biology (IMCB), A*STAR, Singapore in 2003 as a Principal Investigator. He then joined A*STAR’s Institute of Medical Biology (IMB) in 2008, shortly after its inception, to further his research in regenerative medicine, serving as Senior Principal Investigator of the Glycotherapeutics Group. In October 2020, Professor Cool re-joined the Institute of Molecular and Cell Biology (IMCB) as a Research Director, Glycotherapeutics, where he focused on developing novel glycosaminoglycan biomolecules that enhance wound repair and control adult human mesenchymal stem cell activity.

Professor Cool has 117 patent applications across 26 families with 51 granted in the fields of glycosaminoglycan biochemistry, regenerative medicine and stem cell science. He has more than 150 publications and continues to foster strong strategic collaborations both nationally and internationally with academic and industry groups. He has a strong biomanufacturing and translational focus with experience in taking glycosaminoglycan-based devices through discovery RnD on to pre-clinical and clinical testing. Professor Cool also has an entrepreneurial and licensing background having successfully spun-off some of his technology to a US-based regenerative medicine start-up company, SMC Biotechnology Ltd. Professor Cool holds a Visiting Professor appointment at the Institute of Molecular and Cell Biology (IMCB), A*STAR, Singapore and an Adjunct Professor (Research) appointment in the Orthopaedic Department at the National University of Singapore (NUS). Prior to his move back to UQ, he previously held the position of Treasurer, Tissue Engineering and Regenerative Medicine International Society, Asia Pacific Chapter (TERMIS-AP) and Treasurer, Stem Cell Society Singapore (SCSS). He also held senior leadership positions in several Singapore-based R&D programmes, notably as Director, Allogeneic Stem Cell Manufacturing (ASTEM) and Theme Leader in Advanced Manufacturing for Biological Materials (AMBM). Prof Cool currently serves on the Editorial Board of the journals Biomaterials, Tissue Engineering and Regenerative Medicine, and is Asia-Pacific Regional Editor for Stem Cells and Development.

Availability

Professor Simon Cool is:
Available for supervision

Qualifications

  • Bachelor of Science (Honours), unknown
  • PhD, unknown

Research interests

  • Manufacturing highly-potent stem cells

    Developing novel media, assays, and processes to enable the scale-up manufacturing of cell therapy products.

  • Rejuvenation of ageing stem cells

    Developing innovative methods to rejuvenate ageing stem cells to generate best-in-class cell banks for therapeutic use.

  • Synthesis of glycosaminoglycans as medical devices

    Developing scalable methods to manufacture fully synthetic glycosaminoglycans for use as media additives, biocoatings and medical devices for treating disease, injury or trauma.

  • Modification of stem cells to improve their therapeutic utility

    Altering stem cell surfaces to encourage protein binding and drive stem cell fate decisions for improved therapeutic efficacy.

  • Enhanced angiogenesis through glycosaminoglycan administration and medical device formulation

    Developing pro-angiogenic microenvironments using novel glycosaminoglycan formulations.

Research impacts

I have over 25 years of leadership in identifying novel heparan sulphate (HS) glycosaminoglycan (GAG) sugars within stem cell niches and repairing tissues. These sugars sequester, protect, hold, and present key growth factors to stem cells. I have successfully used this complexation paradigm to unlock pathways critical to stem cell biology, mainly signalling cascades essential for maintaining naïve phenotypes. I have also shown that this strategy effectively develops bioadditives for manufacturing cell therapy devices for treating vascular ischemia/stroke, cartilage regeneration, and bone repair. A significant part of this pioneering effort has been manufacturing HS variants that mimic sugars in native tissues. Anchoring this strategy is my novel discovery platform that identifies specific domains in HS chains that form complexes with growth factors and growth factor receptors to generate powerful signalling complexes that mediate cell-fate decisions and potentiate tissue regeneration. Using this blueprint, I have developed a library of bio-inspired HS variants and subjected them to structure/function analyses. I strongly advocate for the safety/tolerability testing of HS materials and continue to lead industry-based projects in this area. I have considerable experience leading outcome-focused multidisciplinary research teams across all scientific discovery and translation aspects, with a proven track record in developing transformative technology and biotechnology entrepreneurship. I lead a long-standing effort to bank mesenchymal stem cells cultured in HS-supplemented media to treat age-related diseases (pre-clinical stage only) and have been working to transition this project to a commercial facility to develop suitable manufacturing and banking protocols for future clinical testing. Through these various opportunities, I have mentored numerous PhD students in Australia, Singapore, and the UK, which has helped accelerate research opportunities and led to significant gains in generating novel findings.

Works

Search Professor Simon Cool’s works on UQ eSpace

166 works between 1996 and 2024

21 - 40 of 166 works

2020

Journal Article

Heparan sulfate proteoglycans: key mediators of stem cell function

Ravikumar, Maanasa, Smith, Raymond Alexander Alfred, Nurcombe, Victor and Cool, Simon M. (2020). Heparan sulfate proteoglycans: key mediators of stem cell function. Frontiers in Cell and Developmental Biology, 8 581213, 581213. doi: 10.3389/fcell.2020.581213

Heparan sulfate proteoglycans: key mediators of stem cell function

2020

Journal Article

A genomic biomarker that identifies human bone marrow-derived mesenchymal stem cells with high scalability

Sathiyanathan, Padmapriya, Samsonraj, Rebekah M., Tan, Clarissa L. L., Ling, Ling, Lezhava, Alexander, Nurconnbe, Victor, Stanton, Lawrence W. and Cool, Simon M. (2020). A genomic biomarker that identifies human bone marrow-derived mesenchymal stem cells with high scalability. Stem Cells, 38 (9), 1124-1136. doi: 10.1002/stem.3203

A genomic biomarker that identifies human bone marrow-derived mesenchymal stem cells with high scalability

2020

Journal Article

Vascular endothelial growth factor 165-binding heparan sulfate promotes functional recovery from cerebral ischemia

Chan, Su Jing, Esposito, Elga, Hayakawa, Kazuhide, Mandaville, Emiri, Smith, Raymond A. A., Guo, Shuzhen, Niu, Wanting, Wong, Peter Tsun-Hong, Cool, Simon M., Lo, Eng H. and Nurcombe, Victor (2020). Vascular endothelial growth factor 165-binding heparan sulfate promotes functional recovery from cerebral ischemia. Stroke, 51 (9), 2844-2853. doi: 10.1161/STROKEAHA.119.025304

Vascular endothelial growth factor 165-binding heparan sulfate promotes functional recovery from cerebral ischemia

2020

Journal Article

In reply

Cool, Simon M., Sathiyanathan, Padmapriya, Samsonraj, Rebekah M., Tan, Clarissa L. L., Ling, Ling, Lezhava, Alexander, Nurcombe, Victor and Stanton, Lawrence W. (2020). In reply. Stem Cells, 38 (11), E7-E8. doi: 10.1002/stem.3264

In reply

2020

Journal Article

Inhibition of the epigenetic suppressor EZH2 primes osteogenic differentiation mediated by BMP2

Dudakovic, Amel, Samsonraj, Rebekah M., Paradise, Christopher R., Galeano-Garces, Catalina, Mol, Merel O., Galeano-Garces, Daniela, Zan, Pengfei, Galvan, M Lizeth, Hevesi, Mario, Pichurin, Oksana, Thaler, Roman, Begun, Dana L., Kloen, Peter, Karperien, Marcel, Larson, A. Noelle, Westendorf, Jennifer J., Cool, Simon M. and van Wijnen, Andre J. (2020). Inhibition of the epigenetic suppressor EZH2 primes osteogenic differentiation mediated by BMP2. The Journal of Biological Chemistry, 295 (23), 7877-7893. doi: 10.1074/jbc.RA119.011685

Inhibition of the epigenetic suppressor EZH2 primes osteogenic differentiation mediated by BMP2

2020

Conference Publication

A synthetic heparan sulphate mimetic for enhancing BMP-2-mediated osteogenesis and bone regeneration

Smith, R.A., Lu, X., Tan, T., Luo, X., Le, B.Q., Zubkova, O.V., Cool, S. and Nurcombe, V. (2020). A synthetic heparan sulphate mimetic for enhancing BMP-2-mediated osteogenesis and bone regeneration. ISCT 2020, Paris, France, 26-29 May 2020. Oxford, United Kingdom: Elsevier. doi: 10.1016/j.jcyt.2020.03.017

A synthetic heparan sulphate mimetic for enhancing BMP-2-mediated osteogenesis and bone regeneration

2020

Journal Article

Ascorbate and iron are required for the specification and long-term self-renewal of human skeletal mesenchymal stromal cells

Liu, Tong Ming, Yildirim, Ege Deniz, Li, Pin, Fang, Hai Tong, Denslin, Vinitha, Kumar, Vibhor, Loh, Yuin Han, Lee, Eng Hin, Cool, Simon M., Teh, Bin Tean, Hui, James H., Lim, Bing and Shyh-Chang, Ng (2020). Ascorbate and iron are required for the specification and long-term self-renewal of human skeletal mesenchymal stromal cells. Stem Cell Reports, 14 (2), 210-225. doi: 10.1016/j.stemcr.2020.01.002

Ascorbate and iron are required for the specification and long-term self-renewal of human skeletal mesenchymal stromal cells

2020

Journal Article

Enhancing the efficacy of stem cell therapy with glycosaminoglycans

Ling, Ling, Ren, Xiafei, Cao, Xue, Hassan, Afizah Binte Mohd, Mah, Sophia, Sathiyanathan, Padmapriya, Smith, Raymond A. A., Tan, Clarissa L. L., Eio, Michelle, Samsonraj, Rebekah M., Van Wijnen, Andre J., Raghunath, Michael, Nurcombe, Victor, Hui, James H. and Cool, Simon M. (2020). Enhancing the efficacy of stem cell therapy with glycosaminoglycans. Stem Cell Reports, 14 (1), 105-121. doi: 10.1016/j.stemcr.2019.12.003

Enhancing the efficacy of stem cell therapy with glycosaminoglycans

2019

Journal Article

Bringing heparan sulfate glycomics together with proteomics for the design of novel therapeutics: A historical perspective

Nurcombe, Victor, Ling, Ling, Hondermarck, Hubert, Cool, Simon M. and Smith, Raymond A. A. (2019). Bringing heparan sulfate glycomics together with proteomics for the design of novel therapeutics: A historical perspective. Proteomics, 19 (21-22) 1800466, 1800466. doi: 10.1002/pmic.201800466

Bringing heparan sulfate glycomics together with proteomics for the design of novel therapeutics: A historical perspective

2019

Journal Article

Vascular cells and tissue constructs derived from human pluripotent stem cells for toxicological screening

Titmarsh, Drew M., Nurcombe, Victor, Cheung, Christine and Cool, Simon M. (2019). Vascular cells and tissue constructs derived from human pluripotent stem cells for toxicological screening. Stem Cells and Development, 28 (20), 1347-1364. doi: 10.1089/scd.2018.0246

Vascular cells and tissue constructs derived from human pluripotent stem cells for toxicological screening

2019

Conference Publication

Biomimicry of glycosaminoglycans in the bone marrow microenvironment favour the expansion of highly potent human mesenchymal stem cells

Ling, L., Ren, X., Hassan, A. Binte Mohd, Mah, S., Smith, R. A., Tan, C., van Wijnen, A., Raghunath, M., Nurcombe, V., Hui, J. and Cool, S. (2019). Biomimicry of glycosaminoglycans in the bone marrow microenvironment favour the expansion of highly potent human mesenchymal stem cells. ISCT 2019, Melbourne, VIC Australia, 29 May - 1 June 2019. Oxford, United Kingdom: Elsevier. doi: 10.1016/j.jcyt.2019.03.463

Biomimicry of glycosaminoglycans in the bone marrow microenvironment favour the expansion of highly potent human mesenchymal stem cells

2019

Journal Article

A heparan sulfate device for the regeneration of osteochondral defects

Lee, Jonathan H., Luo, Xiaoman, Ren, Xiafei, Tan, Tuan Chun, Smith, Raymond A.A., Swaminathan, Kunchithapadam, Sekar, Sakthivel, Bhakoo, Kishore, Nurcombe, Victor, Hui, James H. and Cool, Simon M. (2019). A heparan sulfate device for the regeneration of osteochondral defects. Tissue Engineering - Part A, 25 (5-6), 352-363. doi: 10.1089/ten.tea.2018.0171

A heparan sulfate device for the regeneration of osteochondral defects

2019

Journal Article

Autologous bone marrow clot as an alternative to autograft for bone defect healing

Lim, Z. X.H., Rai, B., Tan, T. C., Ramruttun, A. K., Hui, J. H., Nurcombe, V., Teoh, S. H. and Cool, S. M. (2019). Autologous bone marrow clot as an alternative to autograft for bone defect healing. Bone and Joint Research, 8 (3), 107-117. doi: 10.1302/2046-3758.83.BJR-2018-0096.R1

Autologous bone marrow clot as an alternative to autograft for bone defect healing

2019

Journal Article

A polycaprolactone-beta-tricalcium phosphateeheparan sulphate device for cranioplasty

Le, Bach Quang, Rai, Bina, Lim, Zophia Xue Hui, Tan, Tuan Chun, Lin, Tingxuan, Lee, Jaslyn Jie Lin, Murali, Sadasivam, Teoh, Swee Hin, Nurcombe, Victor and Cool, Simon McKenzie (2019). A polycaprolactone-beta-tricalcium phosphateeheparan sulphate device for cranioplasty. Journal of Cranio-Maxillofacial Surgery, 47 (2), 341-348. doi: 10.1016/j.jcms.2018.11.013

A polycaprolactone-beta-tricalcium phosphateeheparan sulphate device for cranioplasty

Featured

2018

Journal Article

Minimum structural requirements for BMP-2-binding of heparin oligosaccharides

Smith, Raymond A.A., Murali, Sadasivam, Rai, Bina, Lu, Xiaohua, Lim, Zophia Xue Hui, Lee, Jaslyn J.L., Nurcombe, Victor and Cool, Simon M. (2018). Minimum structural requirements for BMP-2-binding of heparin oligosaccharides. Biomaterials, 184, 41-55. doi: 10.1016/j.biomaterials.2018.08.056

Minimum structural requirements for BMP-2-binding of heparin oligosaccharides

2018

Journal Article

Improved recovery from limb ischaemia by delivery of an affinity-isolated heparan sulphate

Poon, Selina, Lu, Xiaohua, Smith, Raymond A. A., Ho, Pei, Bhakoo, Kishore, Nurcombe, Victor and Cool, Simon M. (2018). Improved recovery from limb ischaemia by delivery of an affinity-isolated heparan sulphate. Angiogenesis, 21 (4), 777-791. doi: 10.1007/s10456-018-9622-9

Improved recovery from limb ischaemia by delivery of an affinity-isolated heparan sulphate

2018

Journal Article

Validation of osteogenic properties of cytochalasin D by high-resolution RNA-sequencing in mesenchymal stem cells derived from bone marrow and adipose tissues

Samsonraj, Rebekah M., Paradise, Christopher R., Dudakovic, Amel, Sen, Buer, Nair, Asha A., Dietz, Allan B., Deyle, David R., Cool, Simon M., Rubin, Janet and Van Wijnen, Andre J. (2018). Validation of osteogenic properties of cytochalasin D by high-resolution RNA-sequencing in mesenchymal stem cells derived from bone marrow and adipose tissues. Stem Cells and Development, 27 (16), 1136-1145. doi: 10.1089/scd.2018.0037

Validation of osteogenic properties of cytochalasin D by high-resolution RNA-sequencing in mesenchymal stem cells derived from bone marrow and adipose tissues

2018

Journal Article

Immobilization of vitronectin-binding heparan sulfates onto surfaces to support human pluripotent stem cells

Yap, Lynn, Murali, Sadasivam, Bhakta, Gajadhar, Titmarsh, Drew M., Chen, Allen Kuan-Liang, Chiin Sim, Lyn, Bardor, Muriel, Lim, Yu Ming, Goh, James C.H., Oh, Steve K.W., Choo, Andre B.H., van Wijnen, Andre J., Robinson, David E., Whittle, Jason D., Birch, William R., Short, Robert D., Nurcombe, Victor and Cool, Simon M. (2018). Immobilization of vitronectin-binding heparan sulfates onto surfaces to support human pluripotent stem cells. Journal of Biomedical Materials Research - Part B Applied Biomaterials, 106 (5), 1887-1896. doi: 10.1002/jbm.b.33999

Immobilization of vitronectin-binding heparan sulfates onto surfaces to support human pluripotent stem cells

2018

Journal Article

Fibrin glue mediated delivery of bone anabolic reagents to enhance healing of tendon to bone

Soreide, Endre, Denbeigh, Janet M., Lewallen, Eric A., Samsonraj, Rebekah M., Berglund, Lawrence J., Dudakovic, Amel, Cool, Simon M., Nordsletten, Lars, Kakar, Sanjeev and van Wijnen, Andre J. (2018). Fibrin glue mediated delivery of bone anabolic reagents to enhance healing of tendon to bone. Journal of Cellular Biochemistry, 119 (7), 5715-5724. doi: 10.1002/jcb.26755

Fibrin glue mediated delivery of bone anabolic reagents to enhance healing of tendon to bone

2018

Journal Article

Retention of the structure and function of heparan sulfate biomaterials after gamma irradiation

Smith, Raymond A. A., Chua, R. J. E., Carnachan, Susan M., Tan, Clarissa L. L., Sims, Ian M., Hinkley, Simon F. R., Nurcombe, Victor and Cool, Simon M. (2018). Retention of the structure and function of heparan sulfate biomaterials after gamma irradiation. Tissue Engineering - Part A, 24 (9-10), 729-739. doi: 10.1089/ten.tea.2017.0263

Retention of the structure and function of heparan sulfate biomaterials after gamma irradiation

Funding

Past funding

  • 2003
    DEVELOPMENT OF A NOVEL BIOMATERIAL FOR BONE TISSUE ENGINEERING
    ARC Discovery Projects
    Open grant
  • 2001
    Fibroblast growth factors and their effects on bone mesenchymal stem cells.
    UQ Early Career Researcher
    Open grant
  • 2000 - 2003
    Promotion of bone healing by exogenous applications of growth factors
    Wesley Merdical Research
    Open grant
  • 1999
    Fibroblast growth factor: unlocking the secrets of osteoblast growth, differentiation and apoptosis.
    UQ New Staff Research Start-Up Fund
    Open grant

Supervision

Availability

Professor Simon Cool is:
Available for supervision

Before you email them, read our advice on how to contact a supervisor.

Available projects

  • Orthopaedic application of glycotherapeutics linked to implantable scaffolds

    We have developed a range of glycosaminoglycan compounds that drive cell fate decisions through complexation with protein/protein receptors that are important for bone formation. Here we seek to coat implantable scaffolds (doi: 10.1116/1.4933109) with these materials and to progress these implantable orthopaedic devices through a range of preclinical models in an effort to define their future clinical utility.

  • Age-related changes in stem cell glycosaminoglycans

    We have identified a range of glycosaminoglycan-altering enzymes that can potentially drive senescent phenotypes linked to stem cell ageing during scale-up manufacturing. Here we seek to develop glycosaminoglycan variants capable of replenishing these lost glycosaminoglycan structures that can restore growth and potency.

Supervision history

Current supervision

Completed supervision

Media

Enquiries

For media enquiries about Professor Simon Cool's areas of expertise, story ideas and help finding experts, contact our Media team:

communications@uq.edu.au